Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
NCT07310095Phase 4Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Achieving Clinical Remission at 48 weeks. Started Dec 2025; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07310095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310095.